Sign up
Quantellect · Analysts · Analyst Profile
Q Score Rank#127 of 449

Ed Arce

HC Wainwright & Co. · Equity Research Analyst
EstablishedRating since 2020No new ratings since Jun 2025

Analyst rating accuracy & track record

Ed Arce is an equity research analyst at HC Wainwright & Co.. Quantellect has scored 131 of their stock calls across 18 companies. Their picks beat their sector 44% of the time over the next 12 months, and their price targets were reached 13% of the time within a year.

Win % vs sector
44%
PT Hit % (12mo)
13%
Avg sector-excess
−0.3%
Scored calls
131
Tickers
18
Tier
Established

Track record

Quantellect has scored 131 of Ed Arce's stock calls across 18 companies, dating back to 2020. Their rated stocks beat their own sector 44% of the time over the next 12 months. On a typical call, a Arce pick returned −0.3% more than its sector over the following year.

Of the scored calls, 131 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
TVTXTravere Therapeutics Inc
Buy$30.00Jun 2025+212.7%Hit
MTVAMetaVia Inc.
Buy$12.00Apr 2025−92.9%Miss
UNCYUnicycive Therapeutics Inc
Buy$7.50Apr 2025−0.2%Miss
ARCTArcturus Therapeutics Holdings Inc
Buy$60.00Apr 2025−23.4%Miss
AKBAAkebia Ther
Buy$7.50Apr 2025−36.1%Miss
IVAInventiva Sa
Buy$13.00Apr 2025+76.7%Miss
UNCYUnicycive Therapeutics Inc
Buy$7.50Apr 2025+25.5%Miss
ALGSAligos Therapeutics Inc
Buy$70.00Mar 2025−0.0%Miss
IVAInventiva Sa
Buy$13.00Mar 2025+86.1%Miss
MTVAMetaVia Inc.
Buy$12.00Mar 2025−91.7%Miss
ACXPAcurx Pharmaceuticals LLC
Buy$12.00Mar 2025−22.4%Miss
AKBAAkebia Ther
Buy$7.50Mar 2025−41.8%Miss
SGMTSagimet Biosciences Inc. Series A Common Stock
Buy$32.00Mar 2025+34.1%Miss
ALGSAligos Therapeutics Inc
Buy$70.00Mar 2025−37.5%Miss
SGMTSagimet Biosciences Inc. Series A Common Stock
Buy$32.00Mar 2025+56.0%Miss
ARCTArcturus Therapeutics Holdings Inc
Buy$60.00Mar 2025−54.8%Miss
ARCTArcturus Therapeutics Holdings Inc
Buy$63.00Feb 2025−66.2%Miss
RAREUltragenyx
Buy$95.00Feb 2025−63.4%Miss
ARCTArcturus Therapeutics Holdings Inc
Buy$63.00Feb 2025−69.0%Miss
RAREUltragenyx
Buy$95.00Feb 2025−64.5%Miss
ENTAEnanta Pharmaceuticals Inc
Buy$18.00Feb 2025+134.1%Miss
IVAInventiva Sa
Buy$13.00Jan 2025+146.8%Miss
UNCYUnicycive Therapeutics Inc
Buy$4.00Jan 2025+8.8%Miss
AKBAAkebia Ther
Buy$7.50Jan 2025−53.9%Miss
ABUSArbutus Biopharma Corp
Buy$5.00Jan 2025+15.3%Hit
AKBAAkebia Ther
Buy$7.50Jan 2025−43.1%Miss
ACXPAcurx Pharmaceuticals LLC
Buy$12.00Jan 2025−94.4%Miss
ACXPAcurx Pharmaceuticals LLC
Buy$12.00Jan 2025−93.4%Miss
UNCYUnicycive Therapeutics Inc
Buy$4.00Jan 2025−23.1%Miss
MTVAMetaVia Inc.
Buy$12.00Dec 2024−76.5%Miss
ENTAEnanta Pharmaceuticals Inc
Buy$18.00Dec 2024+163.1%Miss
RAREUltragenyx
Buy$95.00Dec 2024−34.7%Miss
ACXPAcurx Pharmaceuticals LLC
Buy$12.00Dec 2024−84.7%Miss
ABUSArbutus Biopharma Corp
Buy$5.00Nov 2024+17.5%Hit
SGMTSagimet Biosciences Inc. Series A Common Stock
Buy$32.00Nov 2024+70.3%Miss
ACXPAcurx Pharmaceuticals LLC
Buy$12.00Nov 2024−95.6%Miss
UNCYUnicycive Therapeutics Inc
Buy$2.50Nov 2024+1.6%Miss
ALGSAligos Therapeutics Inc
Buy$75.00Nov 2024−29.7%Miss
ABUSArbutus Biopharma Corp
Buy$5.00Nov 2024+21.0%Hit
RAREUltragenyx
Buy$95.00Nov 2024−38.3%Miss
ARDXArdelyx Inc
Buy$11.00Nov 2024+0.3%Miss
SGMTSagimet Biosciences Inc. Series A Common Stock
Buy$32.00Oct 2024+60.5%Miss
ALGSAligos Therapeutics Inc
Buy$75.00Oct 2024+5.6%Miss
AKBAAkebia Ther
Buy$7.50Oct 2024+89.1%Miss
IVAInventiva Sa
Buy$13.00Oct 2024+131.4%Miss
AKBAAkebia Ther
Buy$7.50Oct 2024+114.3%Miss
ENTAEnanta Pharmaceuticals Inc
Buy$27.00Oct 2024+5.8%Miss
UNCYUnicycive Therapeutics Inc
Buy$2.50Oct 2024+35.7%Miss
AKBAAkebia Ther
Buy$7.50Oct 2024+126.7%Miss
SGMTSagimet Biosciences Inc. Series A Common Stock
Buy$32.00Oct 2024+77.6%Miss
Prev1
Go to

Ed Arce: analyst track record FAQ

Is Ed Arce a good stock analyst?

Yes, by track record. Ed Arce ranks number 127 of 449 of the analysts Quantellect scores, with a Q Score of 49 out of 100. Past results do not guarantee future ones.

What is Ed Arce's win rate?

Ed Arce's win rate is 44%. Across 131 scored calls, their rated stocks beat their sector 44% of the time over the next 12 months. On a typical call they returned −0.3% more than the sector.

What stocks and sectors does Ed Arce cover?

Ed Arce covers 18 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Ed Arce's price targets accurate?

Ed Arce's price targets are reached within 12 months 13% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Ed Arce's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Ed Arce rank among Wall Street analysts?

Ed Arce ranks number 127 of 449 by Q Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.